Endo International plc – (NASDAQ:ENDP) (TSE:ENL) was the recipient of a significant drop in short interest during the month of December. As of December 29th, there was short interest totalling 20,250,569 shares, a drop of 13.5% from the December 15th total of 23,402,027 shares. Based on an average daily volume of 3,647,667 shares, the short-interest ratio is currently 5.6 days. Approximately 10.1% of the company’s stock are sold short.
Several research firms have recently issued reports on ENDP. ValuEngine lowered shares of Endo International from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Leerink Swann began coverage on shares of Endo International in a report on Tuesday, January 2nd. They set an “outperform” rating and a $12.00 target price for the company. Zacks Investment Research lowered shares of Endo International from a “hold” rating to a “sell” rating in a report on Thursday, October 26th. Vetr lowered shares of Endo International from a “strong-buy” rating to a “buy” rating and set a $8.92 target price for the company. in a report on Monday, December 18th. Finally, Citigroup lowered their target price on shares of Endo International from $9.00 to $7.00 and set a “neutral” rating for the company in a report on Friday, November 10th. Three research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $11.27.
Shares of Endo International (ENDP) opened at $7.95 on Friday. The company has a debt-to-equity ratio of 10.78, a current ratio of 1.08 and a quick ratio of 0.86. Endo International has a 1 year low of $5.77 and a 1 year high of $14.45. The company has a market cap of $1,770.00, a P/E ratio of -0.41, a price-to-earnings-growth ratio of 2.98 and a beta of 0.59.
Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its earnings results on Thursday, November 9th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.06. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. The business had revenue of $786.90 million during the quarter, compared to the consensus estimate of $794.93 million. During the same quarter in the previous year, the firm posted $1.01 EPS. The firm’s revenue was down 11.0% on a year-over-year basis. equities analysts expect that Endo International will post 3.67 earnings per share for the current year.
Large investors have recently bought and sold shares of the business. LMR Partners LLP bought a new stake in shares of Endo International during the 3rd quarter valued at $148,000. Riverhead Capital Management LLC grew its position in shares of Endo International by 64.4% during the 2nd quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock valued at $168,000 after acquiring an additional 5,887 shares during the period. Bank of Hawaii bought a new stake in shares of Endo International during the 2nd quarter valued at $180,000. Flinton Capital Management LLC grew its position in shares of Endo International by 64.4% during the 2nd quarter. Flinton Capital Management LLC now owns 20,400 shares of the company’s stock valued at $228,000 after acquiring an additional 7,990 shares during the period. Finally, Nisa Investment Advisors LLC bought a new stake in shares of Endo International during the 4th quarter valued at $236,000. 93.06% of the stock is owned by institutional investors and hedge funds.
Endo International Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.